The antibody (Ab) l response of A/J mice to the p-azobenzenearsonate (ABA) hapten includes a substantial cross-reactive idiotypic (CRI or IdX) component (1). Serological (2) and amino acid sequence (3-5) studies on ABA-specific monoclonal Abs (mAb or HP) produced by hybridomas (derived using A/J ABAhyperimmune splenocytes) have indicated that all the HP examined are unique. However, CRI + HP can be shown to share one or more conserved IdX determinant(s) (6). Despite the microheterogeneity of the family of molecules bearing the major CRI, it appears that the heavy chain variable (VH), and probably the light chain variable (VL) regions are each encoded by a single germline gene that undergoes somatic variation (7, 8) . Recently, Milner and Capra (9) showed that the available N-terminal VH sequences could be classed into three distinct VH homology families, which might be termed: (a) the CRIA group (prototypes HP: R16.7, 93G7 [2], and 36-65 [4]); (b) the CRIc, family (prototypes: HP 92D5 [9] and 36-60 [10]); and, (c) the 96B8 family, which has not previously been serologically detected as a distinct IdX entity in the Ab response. It seems likely that these homology families result from the expression of at least three different Vu genes present in the strain A germline.
Breeding pairs of CBA/N mice were obtained from the National Institutes of Health. F~ progeny of CBA/N and A/J mice were bred at U.C., San Francisco.
Antigens and hnmunization. ABA-KLH and ABA-CGG were prepared as described (15) . ABA-Brucella was prepared according to Lucas and Henry (14) , ie., by direct diazotization. Purified Salmonella typhimurium lipopolysaccharide (LPS) was purchased from the List Biological Laboratories, Inc., Campbell, CA, and reacted with an equal mass quantity (10 rag) of the N-hydroxysuccinimide conjugate of p-hydroxyphenylpropionic acid (the latter derivative being prepared according to Pohlit et al. [16] ) in 2 ml dimethyl sulfoxide at room temperature. The product was extensively dialyzed against borate buffer (pH 9.0) and then phosphate-buffered saline (pH 7.3), before conjugation with 1 ml 1 M ABA-diazonium salt and further dialysis.
The TD Ags were emulsified in complete Difco adjuvant H37Ra (Difco Laboratories, Detroit, MI) and injected i.p., ABA-LPS was injected i.p. in PBS only, while ABA-Bru (in PBS) was injected i.v. into a lateral tail vein.
Antisera. The standard Rbt anti-CRI was prepared according to Ju et al. (17) . Preparation of anti-Id (R16.7) and anti-CRIm (anti-CRI adsorbed on an HP R16.7-Sepharose 4B column) has been described elsewhere (11, 13) .
Monoclonal Abs to Thy-1.2 and Lyt-2.2 were produced by the murine hybridoma cells, H O-13 and HO-2.2 (American Type Culture Collection, Bethesda, M D). For Ab-mediated cytotoxic elimination of lymphoid cell subsets, optimal dilutions of the appropriate supernate were employed along with agarose-adsorbed guinea pig complement (C; Gibco Laboratories, Grand Island, NY).
A preparation of the rat anti-CRI mAb AD8 was provided by P. Hornbeck, U.C. San Francisco (18) . For plaque inhibition 10 #1 of a 0.5 mg/ml solution in PBS was used.
Cultures. Splenocytes were adjusted to either 5 × 10e/ml (for ABA-Bru or ABA-LPS cultures) or 107/ml (for SRC cultures) in culture medium (RPMI-1640 + 10% fetal calf serum; Gibco Laboratories), plated in 0.5-ml cultures, and left for 3 d at 37°C, without rocking (SRC cultures were rocked), in an atmosphere of 7% 02, 10% CO2, and 83% N2. Ag concentrations used were: 1/200 final dilution ABA-Bru, 1 #g/ml ABA-LPS, or 15 ul per culture of a 0.1% suspension of SRC (Colorado Serum Co., Denver, CO). Triplicate cultures were pooled and assayed. Results from at least four separate experiments are given for each in vitro data point.
Hemolytic Plaque Assay. The procedure for the plaque assay (15) was modified so that all antisera (anti-IdX, anti-IgM, or anti-IgG) and C, were added directly to the agar. The conjugation of target erythrocytes with the ABA-HB-imidoester was altered from the protocol of Isakson et al. (19) as follows: (a) the concentration of RC in the haptenating mixture was 1/2.5 rather than 1/5; (b) the haptenation mixture was rocked for no more than 13 h; and (c) horse-or goat-RC were substituted for sheep-RC. (HB refers to the phydroxybenzimidate group.) Serological Assays. Anti-ABA Abs were isolated by affinity chromatography on an ABA-BGG-Sepharose 4B column (13) . Radiolabeling of Abs was done in the solid phase as described by Herzenberg and Herzenberg (20) . Briefly, 10 t~g of a pool of anti-ABA Abs was passed over an ABA-BGG-Sepharose 4B column, washed, iodinated with 125I by the chloramine-T method (21) and washed again. Labeled Abs were eluted with 0.5 M parsanilic acid plus 1 mg/ml BSA, pH 8.0. Eluted Abs were exhaustively dialyzed. Anti-ABA titers were determined as given elsewhere (1).
Adoptive Transfers. In the adoptive transfer protocol (22) recipient mice were irradiated (600 tad) -~6 h before reconstitution with splenocytes; and were challenged with Ag (0.2 ml 1.25% ABA-Bru solution i.v. or 0.2 ml 10% SRC, i.p.) 12 h after reconstitution. Mice were maintained on acidified water.
ld Calculations and Statistics. Nonspecific plaque numbers were subtracted from all PFC numbers before calculation of percent IdX ÷ PFC by the formula given previously (15) . The statistical significance of differences of values in two distinct groups was determined using the nonparametric (Wilcoxon) rank sum test or Student's t test for independent groups (23). In the next assays, a polyspecific rabbit antiserum directed to the Id of HP R 16.7 (i.e., the defining antiserum for CRIA positivity) was used to examine antibody responses. A/J mice hyperimmunized with ABA-Bru produced sufficiently high titers of anti-AAB Abs (mostly IgG) for serological analysis, Sera were obtained from A/J mice hyperimmunized (>3 injections) with either ABABru (5 mice) or ABA-KLH (4 mice) and tested for total content of anti-ABA Abs and the proportion that was CRIA +. The data in Table II indicate, first, that the anti-ABA titers of the ABA-Bru sera averaged "~20 times lower than those of the ABA-KLH sera. This result is different than that seen in the plaque assay, in which hyperimmune responses to these two Ags were often comparable ( Table  I ). The discrepancy may reflect the fact that the serum Ab assay detects Ab accumulation, whereas the PFC analysis provides an "instantaneous" picture only.
Results

Disparities
Anti-ABA Abs from serum samples were affinity-purified and tested for their capacity to inhibit the binding of ~25I-labeled HP R16.7 to Rbt anti-CRI (Table  II, column 3 ). An average of 39 ng of Abs from the ABA-KLH sera was required to cause 50% inhibition, whereas -~7 times as much--282 ng--was required from the ABA-Bru sera. This demonstrates that, on a proportional basis, ABAspecific Abs induced by ABA-KLH contained seven times as much CRIA as those induced by ABA-Bru. However, a substantial fraction of the Abs in the anti-ABA-Bru sera was nonetheless CRI +, as shown by the data in the last four columns of Table II . A pool of ABA-specific Abs from the ABA-Bru sera was prepared by combining equal weight quantities from each of the samples, and labeled with 125I. A total of 42% of the Ab (which is 60% of the maximum precipitable by anti-Fab) could be precipitated with the anti-Id (R 16.7) and anti-CRI,,. (Anti-CRIm is a Rbt anti-CRI serum preadsorbed on an HP R16.7- Sepharose 4B column.) Interestingly, more than twice as much material was precipitable with the anti-CRIm serum as with the anti-Id R 16.7 serum (30% vs. 12%, respectively). This result has never been seen with anti-ABA Abs induced by ABA-KLH. For comparison, results obtained using pooled anti-ABA Abs from ABA-KLH sera (different from those used in the inhibition assay) are also presented in Table II . 72% of these Abs were precipitable with Rbt anti-CRI and 55% with Rbt anti-Id R16.7, indicating that 76% of the CRI ÷ Abs were CRIA +, while only ,~ 24% were CRIm +. Except for the somewhat high percentage of CRI ÷ Abs (30-50% is more typical), this result is similar to those reported previously by Brown et ai. (11) . The same question was explored by plaque analysis, using anti-Id R16.7 as an inhibitor. The results in Table III are similar to those obtained using AD8 as an inhibitor of plaques. The ratio values (anti-Id R 16.7/anti-CRI) of 0.92 and 0.96 for ABA-CGG and ABA-KLH, respectively, indicate that >90% of the CRI ÷ PFC induced by these TD Ags were CRIA +. In contrast, only ~ 50-60% of CRI + PFC induced in vivo by ABA-Bru or ABA-LPS, respectively, were CRIA +. Once again, these lower average values reflect the presence of some individual animals with a high, and some with a low relative proportion of CRIA. Note also that CRIA expression was again very weak in the primary in vitro response to ABABru. <30% of the CRI ÷ PFC were CRIA ÷ and this figure may actually be somewhat artifactually inflated due to some nonspecific inhibitory activity (up to 15%) of the particular Rbt anti-Id R16.7 used.
CRIb, Is Only Weakly Expressed in the TI Responses. The preceding data indicate that one or more members of CRIm is at least equi-dominant with CRIA in in vivo responses to ABA TI-1 Ags, and considerably more preponderant in in vitro responses to the same Ags. The possibility was considered that most of the CRIm + PFC induced by the TI Ags were CRIc, +. The data in Table IV 
UC Berkeley). Weak Expression of CRIA in TI Responses Is Probably Not Due to Ts
Cell Activi(v. One possibility to explain the weak expression of CRIA in the TI responses, compared with TD responses, would be that CRIA-specific Ts cells are more active in the former than in the latter. On this basis, if T cells are eliminated it would be expected that the CRIA/CRI ratio would increase in responses to ABABru. To test this, normal or anti-Thy-l.2 plus C-treated spleen cells (2.5 × 106 per 0.5-ml culture) from unprimed or SRC-primed (day -3) A/J mice were cultured in the presence of ABA-Bru or SRC, respectively. Cultures were assayed on day 3. The data (Table V) show that anti-Thy-l.2 treatment did not decrease the number of PFC induced by ABA-Bru, but it did reduce the (secondary) anti-SRC PFC by 85%. (The anti-SRC response has been reported by others to contain a small TI component [24] .) However, the CRIA/CRI ratio was not increased in the cultures containing cells treated with anti-Thy-l.2 plus C; if anything, it decreased somewhat although the difference is not statistically significant. Similar experiments were done using adoptive transfer methodology (lower half of Table V) . Irradiated (600 rad) recipients received 4-5 × 107 normal or anti-Thy-l.2 plus C-treated splenocytes, followed by either ABA-Bru or SRC (control). The results were similar--the CRIA/CRI ratio did not increase. Furthermore, in a few experiments anti-Thy-l.2 treatment was replaced by an elimination step using anti-Lyt-2.2 plus C. Again, comparable results were obtained (data not shown).
b~uence of the xid Defect on CRIa Expression. One of the models that we considered for explaining the preceding data (see Discussion) was that CRIA and CRIm might be asymmetrically expressed by functionally distinct B cell subpopulations. It is known (25) at slightly lower levels than do A/J mice; however, responses by the NAF1 male xid animals were particularly depleted of CRIA. In the response to ABA-Bru by the three normal types of F~ mice, CRIff PFC varied from 2 to 68% of anti-ABA PFC, with means of 35-40% in each case. In contrast, NAFx male responses ranged from 0-29% CRIA + with a mean of 16%, which is significantly lower than the means of all three of the normal groups (P < 0.05).
Discussion
The present data show that the Id profiles of A/J ABA-specific Ab responses induced by TD and TI forms of ABA are distinct. Two different CRI populations, CRIA and CRIm, show differential relative representation in the TI and TD responses. CRIA overwhelmingly dominates (>90%) the CRI ÷ component of the primary in vivo PFC response induced by the TD Ags ABA-KLH and ABA-CGG, at least around the peak of the response (day 9 or 10). Secondary responses to TD Ags also show predominance of CRIA among the CRI + PFC, i.e., >80% of CRI + PFC are CRIA +. This result is in accord with the serologic studies of Brown et al. (11) . In contrast, a significantly lower percentage of CRI + PFC--slightly more on average than 50%--were CRIA + in primary and hyperimmune in vivo responses to ABA-Brucella or ABA-LPS. When individual animals were examined for their CRIA/CRI ratios among primary PFC activated by ABA-KLH or ABA-Bru, values of >0.9 were seen for all animals in the case of the former Ag, whereas, in responses to the TI-1 Ag, ratio values of well below 0.5 were seen in some mice, indicating CRIm predominance. Serologic comparison of the in vivo hyperimmune Abs induced by ABA-Bru and ABA-KLH demonstrated that the CRIA/CRI ratios in the two responses were at least as discrepant, if not more so, than the PFC analysis indicated. However, the weakest expression of CRIA was noted to occur in primary in vitro PFC responses to ABA-Bru and ABA-LPS. Thus, the magnitude of the CRIA/CRI ratio shows the order: 1 ° TD in vivo > 2 ° TD in vivo > 1 °, 2 ° TI in vivo > 1 ° TI in vitro. The CRIm/CRI ratio follows (by definition) exactly the reverse order. The ABA hapten, presented in TI-1 form, appears to activate a more heterogeneous idiotypic response than it does when presented in TD form. The major fraction of the PFC (or Abs) induced by the TI-1 Ags are CRI ÷, but not CRIA +.
One or more members of CRIm is at least equi-dominant with CRIA in ABAspecific TI-l-type Ab responses in A/J mice, in contrast to responses to the potent TD Ags, ABA-KLH or ABA-CGG, where CRIA predominates. But what member(s) of this heterogeneous group (26) is expressed? (Here it might be noted that two nonequivalent definitions for CRIm were previously offered: one based on the presence of direct binding of anti-ABA Abs to Rbt anti-CRI, along with very weak inhibition of the standard CRI-anti-CRI reaction (12) , while the second definition (26) required direct binding by Rbt anti-CRI with concurrent lack of same by Rbt anti-Id R 16.7. The criterion used herein is the second one; PFC inhibition by anti-Id is clearly a direct binding assay.) Several types of CRIm components have been defined. One of these is CRIc, (10, 11) . Data given in this report, however, indicate that CRIc, is only a very minor component in the TI responses, including the in vitro ones. Another class of CRIm + molecules have L chains (but not H chains) corresponding serologically to those present in CRIA + molecules (27) . Another possibility would be that most of the CRIm + Abs are Idrelated to the 96B8 family (9) . Finally, many of the CRIm ÷ Abs might be CRIArelated but represent extensively altered somatic variants that have lost the most immunodominant CRIA-IdX determinants. Further serological and structural analyses of the CRIm + Abs elicited by the TI Ags will be required to pinpoint the exact nature of these.
The most extreme example of Id profile discrepancy from the TD pattern involves the in vitro primary TI responses. The expression of CRIA was considerably weaker in these responses than in in vivo responses to the same Ags. Our data concurs with those presented in a communication of Robertson et al. (28) . These workers reported that none of their ABA-specific B cell hybridomas, generated using A/J lymphocytes polyclonally stimulated in vitro with LPS and dextran sulfate, secreted CRI + Abs. Presumably, CRI positivity was examined using the competition RIA which detects only CRIA + Abs. The unusual Id profile was elicited irrespective of hapten-receptor interaction, since the mitogens used were not ABA-substituted. Thus, the lack of activation of CRIA + clones cannot be attributed to the preferential stimulation of B cells bearing high affinity receptors for ABA. It seems that virgin, ABA-specific, CRIA + B cells may be refractory to in vitro activation. This seems to us to be strongly suggestive evidence that CRIA determinants may be selectively expressed by B cells belonging to a particular subset. It is also likely that this property of CRIA ÷ precursors accounts for our total inability to induce anti-ABA responses in vitro to TD ABA Ags using unprimed A/J B cells, even in the presence of carrier-primed T cells.
The likeliest theories for explaining the present data would invoke the differential activation, in different types of responses, of either B cell subsets or T cell subsets. In the latter case, one could propose, in accordance with the network hypothesis (29) ' that particular Id-specific Th or Ts cells play quantitatively different roles in TI vs. TD responses. The data obtained in the experiments involving anti-Thy-1-(or anti-Lyt-2-) treated A/J splenocytes would, however, tend to rule out enhanced activity of CRIA-specific Ts cells as being responsible for the low CRIA expression observed in the TI responses. This leaves the possibility that CRIA-specific Th cells are more active in in vivo responses to TD ABA Ags than to TI ABA Ags. While it is logically difficult to see why this would be the case, this theory cannot be formally ruled out.
In fact, the hypothesis that seems most consistent with the data is one based on the differential expression of IdX dominance by functionally distinct B cell subpopulations, with the selective activation of these subsets under different conditions. The differential expression of Ig V region elements by different B cell subsets is not a novel idea: Slack et ai. (30) The preceding functional properties attributed to subsets 1 and 2 are not purely speculative but, rather, are based on reported properties of B cells belonging, respectively, to the Lyb-5 ÷ and Lyb-5-subsets (34, 35) . Furthermore, (CBA/N × BALB/c)FI (NBF1) male mice gave almost no primary anti-PC Ab response to PC-KLH in CFA (average 1/10 the female NBF~ response) (36) . This result would suggest that the primary response to this Ag in normal mice is almost entirely attributable to the Lyb-5 + B cell subset, and, as would be expected, is strongly T15-IdX dominant in BALB/c mice (37) .
At first, Sigal's recent evidence (38) that only 2.6% of unprimed ABA-specific B cells from A/J mice are CRIA + would seem to contradict our model. It is possible, however, that there was some bias in the splenic focus assay which resulted in under-representation of CRIA + precursors. In particular, B cells belonging to our hypothetical subset 2 may have been preferentially stimulated.
Finally, we would point out that the two types of theories--the IdX partitioning among different B cell subsets vs. differential Id-specific regulation by T cells--are not totally exclusive. Thus, Lyb-5-B cells may be refractory to helper factors produced by IdX-specific Th cells. Moreover, Lyb-5 ÷ B cells may derive from an Lyb-5-pool (39) . If that is the case, then CRIA-specific Th cells might be envisioned as playing a key role in promoting the selective differentiation of immature CRIA + ABA-specific precursors to the Lyb-5 + subset, which could result in a skewed IdX representation between the two B cell subsets. To test these ideas it would be highly informative if the anti-ABA responses of A/J nu/ nu mice (or B cells therefrom) could be examined.
Summary
Two different cross-reactive idiotype (CRI) groups are distinguishable in the Ab response of A/J mice to the p-azobenzenearsonate (ABA) hapten: CRIA and CRIm. These two groups showed distinct patterns of relative dominance in the ensuing response depending on whether the inducing Ag was a T cell-dependent (TD) form of ABA, such as ABA-KLH or ABA-CGG, or a T-independent type 1 (TI-1) form, such as ABA-Brucella abortus or ABA-lipopolysaccharide (LPS), and on whether the response was elicited in vivo or in vitro. The CRI ÷ component of primary in vivo plaque-forming cell (PFC) responses to TD ABA Ags was largely (>90%) CRIA ÷ as was, to a slightly lesser extent (>75%) the CRI + portion of secondary or hyperimmune serum Ab or PFC responses to the same Ags. In contrast, in vivo primary and hyperimmune PFC responses to ABA-Bru or ABA-LPS showed a significantly lower CRIA/CRI ratio, averaging 0.5-0.6, with some individual mice giving figures as low as 0.2, indicating predominance of CRIm over CRIA. Serological analysis of hyperimmune anti-ABA Abs from a group of 5 A/J mice immunized with ABA-Bru gave a figure of <0.5 for the CRIA/CRI ratio. The most striking disparity from the TD pattern was seen in primary in vitro PFC responses to the TI ABA Ags; here ratios of<0.2 were generally seen. Since T cell removal did not alter the Id pattern in the TI responses, CRIAspecific Ts cells do not account for the weak expression of CRI^ in such responses. We propose a model that explains these results on the basis of differential expression of IdX dominance by two distinct B cell subpopulations--equatable to the Lyb-5 ÷ and Lyb-5-B cell subsets--along with differential relative activation of these subsets in different types of responses. Examination of anti-ABA PFC responses of F~ progeny of CBA/N and A/J mice to ABA-Bru lends support to this hypothesis since CRIA expression was significantly lower in mice with the
